International Biotechnology (LON:IBT - Get Free Report) shares passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 630.43 ($8.46) and traded as high as GBX 632 ($8.49). International Biotechnology shares last traded at GBX 626 ($8.40), with a volume of 240,274 shares trading hands.
International Biotechnology Stock Performance
The firm's 50 day moving average is GBX 589.45 and its 200-day moving average is GBX 629.32. The stock has a market capitalization of £229.90 million, a price-to-earnings ratio of 6.11 and a beta of 0.21.
International Biotechnology (LON:IBT - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported GBX (5.60) (($0.08)) earnings per share (EPS) for the quarter. International Biotechnology had a net margin of 90.66% and a return on equity of 13.67%. As a group, sell-side analysts forecast that International Biotechnology will post 0.9435943 earnings per share for the current year.
Insider Activity
In other news, insider Katherine Cornish-Bowden bought 2,000 shares of the firm's stock in a transaction that occurred on Tuesday, May 13th. The stock was purchased at an average cost of GBX 585 ($7.85) per share, for a total transaction of £11,700 ($15,708.92). 4.18% of the stock is currently owned by corporate insiders.
International Biotechnology Company Profile
(
Get Free Report)
The Company's investment objective is to achieve long-term capital growth by investing in biotechnology and other life sciences companies.
The Company will seek to achieve its objective by investing in a diversified portfolio of companies which may be quoted or unquoted and whose shares are considered to have good growth prospects, with experienced management and strong potential upside through the development and/or commercialisation of a product, device or enabling technology.
Featured Articles
Before you consider International Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and International Biotechnology wasn't on the list.
While International Biotechnology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
